Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Canada Companies

George Abercrombie joins Inspire's board

This article was originally published in Scrip

Executive Summary

Inspire Pharmaceuticals (US) has elected George Abercrombie to its board of directors. Mr Abercrombie most recently served as president and CEO of Roche Inc and head of North American pharmaceutical operations from 2001 to December 2009. During this time, he led the North American pharmaceutical operations for the Roche Group in the US and Canada. From 1997 to 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.

Table

View full table

Topics

Tags:
Canada Companies
Latest Headlines

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

See All
UsernamePublicRestriction

Register

SC007070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By